“Lebrikizumab Confirms a Consistent Safety Profile in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: ​ Data From 11 Trials With Over 3000 Patient-Years of Exposure”. 2025. SKIN The Journal of Cutaneous Medicine 9 (1): s511. https://doi.org/10.25251/skin.9.supp.511.